NEW YORK, Nov 7 (Reuters) - Privately held Prometheus Laboratories Inc said on Wednesday it has agreed to acquire exclusive U.S. rights to GlaxoSmithKline's irritable bowel syndrome drug Lotronex.
The deal for Prometheus is expected to close in the third quarter Terry Lane is a writer for Investopedia with 25 years of experience in journalism and communications. He covers personal finance, ...
Merck & Co. said on Sunday it will buy San Diego’s Prometheus Biosciences for about $10.8 billion, in an effort to build up its presence in immunology. In doing so, Merck will pick up a promising ...
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. At Merck, 2028 is circled on the calendar. The New Jersey pharmaceutical titan’s share price has doubled in the ...
April 17 (Reuters) - Merck & Co (MRK.N), opens new tab expects a research-and-development charge of about $10.3 billion, or $4 per share, this year as the drugmaker accounts its deal for Prometheus ...
The CEER arrays may ultimately be used in clinical trials for patient selection and may potentially accelerate the development of novel oncology therapeutic products. Under the terms of the ...
Merck will acquire Prometheus Biosciences, a clinical-stage biotechnology company specializing in immune-mediated diseases, at a total equity valuation of $10.8 billion. Merck and Prometheus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback